LOGC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LOGC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LogicBio Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2022 was -60.29%.
The historical data trend for LogicBio Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LogicBio Therapeutics Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
ROCE % | Get a 7-Day Free Trial | -45.78 | -33.50 | -59.79 | -49.51 | -66.26 |
LogicBio Therapeutics Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
ROCE % | Get a 7-Day Free Trial | -62.90 | -67.29 | -72.21 | -65.61 | -60.29 |
LogicBio Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | -38.987 | / | ( ( (80.64 - 6.152) | + | (62.77 - 19.583) ) | / 2 ) | |
= | -38.987 | / | ( (74.488 | + | 43.187) | / 2 ) | |
= | -38.987 | / | 58.8375 | ||||
= | -66.26 % |
LogicBio Therapeutics's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | -19.388 | / | ( ( (51.899 - 16.516) | + | (47.017 - 18.085) ) | / 2 ) | |
= | -19.388 | / | ( ( 35.383 | + | 28.932 ) | / 2 ) | |
= | -19.388 | / | 32.1575 | ||||
= | -60.29 % |
(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LogicBio Therapeutics (NAS:LOGC) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of LogicBio Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark J Enyedy | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Mariana Nacht | officer: Chief Scientific Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Daniel Gruskin | officer: Chief Medical Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Susan Kahn | director | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Joshua Blacher | officer: Interim CFO | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Andrea Paul | officer: General Counsel and Secretary | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Frederic Chereau | director, officer: See Remarks | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Kyle Chiang | officer: Chief Operating Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Cecilia Jones | officer: Chief Financial Officer | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Jonathan Quick | officer: Senior Director-Finance | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Jeff Goater | director | C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
Daphne Karydas | director | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Erez Chimovits | director | P.O. BOX 4023, HERZLIYA PITUACH L3 4614001 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 05-27-2022
By PRNewswire PRNewswire • 05-29-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 06-10-2022
By PRNewswire PRNewswire • 05-17-2022
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 05-16-2022
By PRNewswire PRNewswire • 06-08-2022
By PRNewswire PRNewswire • 05-11-2022
By PRNewswire PRNewswire • 06-18-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.